AVEO Pharmaceuticals, Inc. (AVEO)
Chart Events
Performance Outlook
| Previous Close | 6.67 |
| Open | 6.73 |
| Bid | 5.94 x 900 |
| Ask | 6.40 x 800 |
| Day's Range | 6.24 - 6.82 |
| 52 Week Range | 3.06 - 7.55 |
| Volume | |
| Avg. Volume | 221,435 |
| Market Cap | 220.657M |
| Beta (5Y Monthly) | 1.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.20 |
| Earnings Date | Aug 03, 2022 - Aug 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.40 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AVEO
Related Research
- AVEO Pharmaceuticals, Inc.Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total sales are generated in the United States.RatingFair ValueEconomic Moat2 months agoMorningstar
- Simply Wall St.
Strong week for AVEO Pharmaceuticals (NASDAQ:AVEO) shareholders doesn't alleviate pain of five-year loss
This week we saw the AVEO Pharmaceuticals, Inc. ( NASDAQ:AVEO ) share price climb by 20%. But will that heal all the...
- GlobeNewswire
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ERBITUX® (cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients with Recurrent or Metastatic HNSCC
- This agreement follows AVEO’s entry into a similar agreement with Merck KGaA, Darmstadt, Germany to provide cetuximab clinical drug supply outside of the U.S. and Canada - - AVEO Currently Manufacturing Ficlatuzumab Clinical Supply; Potential Phase 3 Registrational Clinical Trial in HPV Negative R/M HNSCC Expected in 1H 2023 - BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it has enter
- GlobeNewswire
AVEO Oncology Announces Updated NCCN Clinical Practice Guidelines Elevate FOTIVDA® (tivozanib) to Category 1 Treatment for Relapsed or Refractory Advanced (R/R) Renal Cell Carcinoma (RCC) Patients
BOSTON, June 21, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the National Comprehensive Cancer Network® (NCCN) has elevated FOTIVDA® (tivozanib) to Category 1 status as a subsequent therapy for RCC patients who have received two or more prior therapies in the latest Kidney Cancer Treatment Guidelines released on June 17, 2022. “Category 1 is the highest Category recommendation offered by NCCN, which is bas
